US 9,006,188 B2Granted

Co-crystals of dapagliflozin

AssigneeMapi Pharma Ltd.

InventorsEhud Marom, Shai Rubnov

Life of this patent

Estimating the term…

Abstract

The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes.

Claims15

Dependent claims

A co-crystal of dapagliflozin with lactose.

Dependencies are inferred from the claim text.

Facts

Application: 14/286,153Filed 23 May 2014 · continuation
Priority: 29 Apr 2013
Published: US 2014/0343010 A120 Nov 2014
Granted: 14 Apr 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/7024
Carbohydrates; Sugars; Derivatives thereof: esters of saccharides
A61K 9/145
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried,…: with…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
C07D 309/10
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…

Family

Application61/816,809Us provisional application · filed 29 Apr 2013
PCT/IL2013/051048Parent of this continuation · filed 23 Dec 2013
US 2014/0343010 A1Pre-grant publication · published 20 Nov 2014
US 9,006,188 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results